These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38992323)

  • 1. Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis.
    Mantovani A; Morandin R; Fiorio V; Lando MG; Petta S; Ferraro PM; Targher G
    Intern Emerg Med; 2024 Sep; 19(6):1745-1755. PubMed ID: 38992323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis.
    Mantovani A; Morandin R; Fiorio V; Lando MG; Gaviraghi A; Motta L; Gobbi F; Tilg H; Byrne CD; Targher G
    Liver Int; 2024 Sep; ():. PubMed ID: 39258758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis.
    Mantovani A; Csermely A; Bilson J; Borella N; Enrico S; Pecoraro B; Shtembari E; Morandin R; Polyzos SA; Valenti L; Tilg H; Byrne CD; Targher G
    Gut; 2024 Aug; 73(9):1554-1561. PubMed ID: 38782564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis.
    Mantovani A; Lando MG; Borella N; Scoccia E; Pecoraro B; Gobbi F; Bisoffi Z; Valenti L; Tilg H; Byrne CD; Targher G
    Liver Int; 2024 Jul; 44(7):1513-1525. PubMed ID: 38567962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.
    Li X; He J; Sun Q
    Clin Nutr; 2024 Sep; 43(9):2005-2016. PubMed ID: 39053329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies.
    Zhang Y; Zhou BG; Zhan JD; Du BB
    Front Oncol; 2024; 14():1366195. PubMed ID: 38567158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies.
    Zhao JF; Zhou BG; Lv Y; Teng QP; Wang XM; Li XY; Ding Y
    Front Oncol; 2024; 14():1368965. PubMed ID: 39045565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis.
    Lv Q; Zhao H
    Ann Med; 2024 Dec; 56(1):2306192. PubMed ID: 38253023
    [No Abstract]   [Full Text] [Related]  

  • 10. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.
    Xiao L; Li Y; Hong C; Ma P; Zhu H; Cui H; Zou X; Wang J; Li R; He J; Liang S; Li Z; Zeng L; Liu L
    J Transl Med; 2024 Jul; 22(1):650. PubMed ID: 38997780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Mantovani A; Nascimbeni F; Lonardo A; Zoppini G; Bonora E; Mantzoros CS; Targher G
    Thyroid; 2018 Oct; 28(10):1270-1284. PubMed ID: 30084737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis.
    Mantovani A; Dauriz M; Byrne CD; Lonardo A; Zoppini G; Bonora E; Targher G
    Metabolism; 2018 Oct; 87():1-12. PubMed ID: 29935236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):351-358. PubMed ID: 38407898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.
    Malik A; Javaid S; Malik MI; Qureshi S
    Ann Hepatol; 2024 Aug; 29(6):101544. PubMed ID: 39214253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.
    Suvarna R; Shetty S; Pappachan JM
    Sci Rep; 2024 Aug; 14(1):19790. PubMed ID: 39187533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: A meta-analysis.
    De Filippo O; Di Pietro G; Nebiolo M; Ribaldone DG; Gatti M; Bruno F; Gallone G; Armandi A; Birtolo LI; Zullino V; Mennini G; Corradini SG; Mancone M; Bugianesi E; Iannaccone M; De Ferrari GM; D'Ascenzo F
    Eur J Clin Invest; 2024 Sep; 54(9):e14188. PubMed ID: 38396359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.
    Xiao S; Liu Y; Fu X; Chen T; Xie W
    Am J Med; 2024 Jul; ():. PubMed ID: 39047929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.